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Dawn of a new therapeutic era for SMA 
 
 
The original papers reporting defects in the survival motor neuron (SMN1) gene as the 
underlying cause of spinal muscular atrophy (SMA) were published more than twenty years 
ago [1]. At the time, the identification of SMA as an essentially mono-genetic disorder was 
heralded as a major research breakthrough that would lead to the rapid development of new 
therapies. And yet, despite over two decades of intensive basic and pre-clinical research, no 
approved treatment options are currently available. Against this background, the new open-
label, phase 2 clinical study by Finkel and colleagues published in this issue of The Lancet [2] 
represents a major milestone on the journey towards a viable therapy.   
 
Mutations in the SMN1 gene render it incapable of generating full-length survival motor neuron 
(SMN) protein [3]. The continuing presence of low levels of SMN protein in SMA patients 
results from the presence of a near-identical SMN2 gene, the copy-number of which influences 
disease severity [4]. This ‘backup’ SMN2 gene has a C→T substitution at an exon splice 
enhancer site that regulates exon 7 inclusion. As a result, only < 25% of SMN2 transcripts 
contain exon 7 and are capable of producing full-length SMN protein. However, the retained 
presence of an SMN2 gene in patients offers an opportunity for the development of therapies 
aimed at increasing levels of functional SMN protein, a strategy found to have remarkable 
potential in pre-clinical animal studies [5-6]. 
 
The Phase 2 clinical study by Finkel and colleagues [2] reports on the delivery of nusinersen, 
a 2’-O-methoxyethyl phosphorothioate-modified antisense drug designed to alter splicing of 
SMN2 pre-mRNA and subsequently increase levels of SMN protein. Although data from a 
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Phase 1 trial of nusinersen in patients with less severe forms of SMA have already been 
published [7], the current study represents the first robust demonstration of safety and 
tolerability, as well as a positive pharmacokinetic profile, for nusinersen following multiple 
intrathecal doses in infants with the most severe form of SMA (Type I). Most importantly, the 
study confirmed successful uptake into motor neurons throughout the spinal cord, as well as 
other neuronal populations throughout the nervous system, leading to increased SMN2 mRNA 
exon 7 inclusion and SMN protein levels. This establishes a critical proof-of-principle that it is 
possible to successfully target SMN2 in order to elevate SMN protein levels across a range of 
affected cell types in SMA patients, without any major adverse consequences.  
 
Finkel and colleagues [2] also present preliminary evidence suggesting that nusinersen can 
deliver incremental improvements in motor function for patients with severe forms of SMA. 
Whilst these findings need to be interpreted cautiously in the context of the obvious limitations 
of a small, open-label interventional trial, they should generate significant encouragement that 
elevating SMN protein levels is likely to be of therapeutic benefit to SMA patients.  
 
Robust conclusions can not yet be drawn concerning the potential ability of nusinersen to 
influence broader aspects of the SMA phenotype, such as a requirement for permanent 
ventilation or age of death. This is largely due to the relatively small number of patients 
enrolled in the study and the need to draw quantitative comparisons with an unrelated, natural 
history case series. Indeed, it should be noted that promising clinical responses were not 
uniformly observed across all infants enrolled on the study. However, the overall direction of 
travel is clearly encouraging, with ongoing/future studies (including Phase 3 trials) likely to 
generate the additional clinical data required to gain a full appreciation of the potential 
therapeutic benefits of nusinersen treatment.  
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As predicted from pre-clinical animal studies, the Finkel et al [2] study indicates that restoration 
of SMN protein can modify disease severity, but does not represent a complete cure. Thus, 
ongoing efforts to develop a second generation of SMA therapies are likely to be key for 
developing fully effective treatments for SMA, applicable to patients with all sub-types of the 
condition. These include efforts to restore SMN protein earlier in disease progression (during 
a critical therapeutic/developmental time-window [8]), to facilitate systemic delivery of 
therapies throughout a range of additional peripheral tissues and organs [9-10], and to target 
additional SMN-independent pathways [11-12]. However, the promise of nusinersen 
demonstrated by Finkel and colleagues [2] represents a major first step forward, indeed a new 
dawn, in developing safe and effective therapy options for SMA that are urgently required.  
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